Trials / Completed
CompletedNCT02368522
Comparative Assessment of Utilization of Antiviral Therapies in Hepatitis C and Effectiveness of Daclatasvir-containing Regimens in Real-life Clinical Care in Europe (CMPASS-EU)
Comparative Assessment of Utilization of Antiviral Therapies in Hepatitis C and Effectiveness of Daclatasvir-containing Regimens in Real-life Clinical Care in Europe
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 920 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study aims to collect information on the current treatment patterns for Hepatitis C in participating countries. There is also a focus on patients receiving a daclatasvir-containing treatment regimen who will be followed prospectively for 12 months after treatment initiation to collect real-world data on effectiveness and safety of the treatment. Additional analysis will differentiate between selected subpopulations.
Conditions
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2017-02-01
- Completion
- 2017-02-01
- First posted
- 2015-02-23
- Last updated
- 2017-03-07
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02368522. Inclusion in this directory is not an endorsement.